Liraglutide dosing reference
Common vial sizes, typical dose ranges, and a free reconstitution calculator pre-configured for Liraglutide. Not medical advice. Always verify against your vial label and your provider's protocol.
Liraglutide reconstitution
Pre-loaded with common Liraglutide values — adjust to your vial.
Inputs
Liraglutide common vial sizes: 3 mg, 6 mg, 18 mg. Typical dose range: 0.6–3 mg. Public clinical dosing guidance. Not medical advice.
for a 0.6 mg dose
- Concentration
- 3.00 mg/ml
- Volume
- 0.200 ml
- Per ml
- 100 u
Not medical advice. Always verify against your vial label and your provider's instructions. Re-check before drawing.
About Liraglutide
GLP-1 receptor agonists slow gastric emptying, increase satiety, and improve glycemic regulation. They are used clinically for type-2 diabetes and chronic weight management. Common compounds include semaglutide, tirzepatide, retatrutide, and liraglutide.
How it's used
Once-weekly subcutaneous injection (daily for liraglutide). Most providers titrate the dose upward over weeks to months to manage side effects. Inject into the abdomen, thigh, or upper arm, rotating sites each dose.
Storage
Reconstituted vials are typically refrigerated at 36–46°F (2–8°C) and used within ~28 days. Do not freeze. Discard if cloudy or discolored. Always follow the storage guidance on your specific vial label.
Watch for
- Nausea, vomiting, diarrhea, constipation — most pronounced in the first weeks of titration
- Reduced appetite (the intended effect, but watch for muscle loss without protein intake)
- Fatigue, headache, dizziness early in titration
- Rare but serious: pancreatitis, gallbladder issues, severe dehydration
Brand names & aliases
Liraglutide is also sold or referenced as Saxenda®, Victoza®. These are registered trademarks of their respective owners and are listed for clinical clarity only — Peptide Calculator Log is not affiliated with, endorsed by, or sponsored by these companies.
Protocols using Liraglutide
Liraglutide vs other GLP-1 peptides
4 compounds comparedReference dose ranges for the glp-1 category. Tap any compound to open its full reference page.
| Compound | Brand names | Typical dose | Vial sizes | Status |
|---|---|---|---|---|
| Liraglutide | Saxenda®, Victoza® | 0.6–3 mg | 3, 6, 18 mg | FDA-approved |
| Semaglutide | Ozempic®, Wegovy®, Rybelsus® | 0.25–2.4 mg | 3, 5, 10 mg | FDA-approved |
| Tirzepatide | Mounjaro®, Zepbound® | 2.5–15 mg | 10, 15, 30, 60 mg | FDA-approved |
| Retatrutide | — | 1–12 mg | 10, 20 mg | Research |
Dose ranges summarized from FDA-approved labels (for approved compounds) and peer-reviewed research (for the rest). See the resources page for source databases.
Liraglutide FAQ
Answers, not hype.
Liraglutide (also marketed as Saxenda®, Victoza®) is a peptide in the GLP-1 category. It is an FDA-approved prescription medication. The dose ranges shown on this site (0.6–3 mg) are summarized from the FDA-approved label.
Liraglutide most commonly ships in 3, 6, 18 mg vials. Typical reconstitution volumes are 1, 2, 3 ml of bacteriostatic water — choose the volume to land on a syringe-friendly unit count for your target dose.
Use the formula concentration = vial mg ÷ BAC water ml, then volume = dose mg ÷ concentration, then units = volume × 100 (for U-100). For example, a 3 mg vial reconstituted with 1 ml gives 3.00 mg/ml — at the typical low dose of 0.6 mg that resolves to 20.0 units. The free reconstitution calculator on this site verifies the math against your specific vial.
Yes. Liraglutide is FDA-approved and sold under brand names including Saxenda, Victoza. The official prescribing information is hosted on NIH's DailyMed.
Common side effects reported in the FDA-approved label for Liraglutide include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), reduced appetite, and fatigue — most pronounced during dose-escalation phases. Less common but serious adverse events are listed in full on the prescribing information at DailyMed; review them before starting.
No. The values shown are reference numbers summarized from authoritative sources — FDA-approved labels for approved compounds and peer-reviewed research for the rest. They are not personalized recommendations. Always follow your prescribing provider's instructions and verify every calculation against your vial label.
References & sources
FDA-approved compoundLiraglutide is an FDA-approved compound. The dose ranges shown above are summarized from the official prescribing information. For dosing decisions, always defer to the FDA-approved label and your prescribing provider — not to this site.
- FDA-approved label (DailyMed)The official FDA-approved prescribing information for Liraglutide, hosted by NIH's DailyMed.
- MedlinePlus drug overviewNIH plain-language summary of Liraglutide — uses, side effects, warnings, what to ask your provider.
- PubMed clinical literaturePeer-reviewed research on Liraglutide — randomized trials, meta-analyses, post-marketing studies.
See the resources page for the full list of databases this site cross-checks against.
Track Liraglutide in the app
History, reminders, body-map injection rotation, Apple Watch logging, and a doctor-ready PDF — all bundled with the calculator.
Download on theApp Store